Literature DB >> 20830238

Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.

Georgi Kirovski1, Erwin Gäbele, Christoph Dorn, Lukas Moleda, Christoph Niessen, Thomas S Weiss, Hella Wobser, Doris Schacherer, Christa Buechler, Hermann E Wasmuth, Claus Hellerbrand.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum ranging from simple steatosis to cirrhosis. Hepatocellular lipid accumulation is a hallmark of both nonalcoholic steatosis and steatohepatitis (NASH). The latter develops upon pro-inflammatory cell infiltration and is widely considered as the first relevant pathophysiological step in NAFLD-progression. The chemokine CCL5/RANTES plays an important role in the progression of hepatic inflammation and fibrosis. We here aimed to investigate its expression in NAFLD. Incubation of primary human hepatocytes with palmitic acid induced a dose-dependent lipid accumulation, and corresponding dose-dependent RANTES induction in vitro. Furthermore, we observed significantly elevated hepatic RANTES expression in a dietary model of NAFLD, in which mice were fed a high-fat diet for 12 weeks. This diet induced significant hepatic steatosis but only minimal inflammation. In contrast to the liver, RANTES expression was not induced in visceral adipose tissue of the group fed with high-fat diet. Finally, RANTES serum levels were elevated in patients with ultrasound-diagnosed NAFLD. In conclusion, our data indicate hepatocytes as cellular source of elevated hepatic as well as circulating RANTES levels in response to hepatic steatosis. Noteworthy, upregulation of RANTES in response to lipid accumulation occurs in the absence of relevant inflammation, which further indicates that hepatic steatosis per se has pathophysiological relevance and should not be considered as benign.

Entities:  

Keywords:  Hepatic steatosis; RANTES; chemokine CCL5; inflammation; liver cirrhosis; nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatosis; steatohepatitis

Mesh:

Substances:

Year:  2010        PMID: 20830238      PMCID: PMC2933387     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

Review 1.  Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective.

Authors:  Leslie R Bisset; Peter Schmid-Grendelmeier
Journal:  Curr Opin Pulm Med       Date:  2005-01       Impact factor: 3.155

2.  Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans.

Authors:  E Novo; F Marra; E Zamara; L Valfrè di Bonzo; L Monitillo; S Cannito; I Petrai; A Mazzocca; A Bonacchi; R S M De Franco; S Colombatto; R Autelli; M Pinzani; M Parola
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

Review 3.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Acta Neurol Scand       Date:  2007-03       Impact factor: 3.209

4.  A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease.

Authors:  Marcus Mühlbauer; Anja K Bosserhoff; Arndt Hartmann; Wolfgang E Thasler; Thomas S Weiss; Hans Herfarth; Guntram Lock; Jürgen Schölmerich; Claus Hellerbrand
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 5.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

6.  The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection.

Authors:  Clovis Palmer; Theresa Corpuz; Marianne Guirguis; Sandra O'Toole; Kenneth Yan; Yagmin Bu; John Jorgenson; Michael Talbot; Kenneth Loi; Andrew Lloyd; Amany Zekry
Journal:  Gut       Date:  2009-03-15       Impact factor: 23.059

7.  Expression of CC chemokine ligand 5 in patients with rheumatoid arthritis and its correlation with disease activity and medication.

Authors:  Ming-hui Yang; Feng-xia Wu; Chuan-mei Xie; Yu-feng Qing; Guang-rong Wang; Xiao-lan Guo; Zhong Tang; Jing-guo Zhou; Guo-hua Yuan
Journal:  Chin Med Sci J       Date:  2009-03

8.  Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes.

Authors:  T S Weiss; B Jahn; M Cetto; K-W Jauch; W E Thasler
Journal:  Cell Prolif       Date:  2002-10       Impact factor: 6.831

9.  Atherogenic diet-induced hepatitis is partially dependent on murine TLR4.

Authors:  Moreshwar S Desai; M Michele Mariscalco; Ahmad Tawil; J G Vallejo; C W Smith
Journal:  J Leukoc Biol       Date:  2008-03-11       Impact factor: 4.962

10.  Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration.

Authors:  Robert F Schwabe; Ramon Bataller; David A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-06-26       Impact factor: 4.052

View more
  20 in total

Review 1.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 2.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  Inflammation-associated upregulation of the sulfated steroid transporter Slc10a6 in mouse liver and macrophage cell lines.

Authors:  Astrid Kosters; Demesew F Abebe; Julio C Felix; Paul A Dawson; Saul J Karpen
Journal:  Hepatol Res       Date:  2015-11-19       Impact factor: 4.288

4.  Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways.

Authors:  Jens U Marquardt; Daekwan Seo; Luis E Gómez-Quiroz; Koichi Uchida; Matthew C Gillen; Mitsuteru Kitade; Pal Kaposi-Novak; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Biochim Biophys Acta       Date:  2012-02-22

5.  New medical treatment strategies for nonalcoholic steatohepatitis.

Authors:  Michael Fuchs
Journal:  Curr Treat Options Gastroenterol       Date:  2015-06

Review 6.  An Update on the Chemokine System in the Development of NAFLD.

Authors:  Naoto Nagata; Guanliang Chen; Liang Xu; Hitoshi Ando
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

7.  A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.

Authors:  Mei Yee Koh; Mihai Gagea; Timothy Sargis; Robert Lemos; Geoffrey Grandjean; Adriana Charbono; Vasileos Bekiaris; John Sedy; Galina Kiriakova; Xiuping Liu; Lewis R Roberts; Carl Ware; Garth Powis
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

Review 8.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 9.  Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

10.  NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Authors:  Geoffrey C Farrell; Derrick van Rooyen; Lay Gan; Shivrakumar Chitturi
Journal:  Gut Liver       Date:  2012-04-17       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.